Chattem Newswire

Chattem Newswire

Comprehensive Real-Time News Feed for Chattem.

Results 1 - 1 of 1 in Chattem

  1. NAD: Allergy Medication Too Smart for Its Own GoodRead the original story w/Photo

    Feb 15, 2018 | JD Supra

    Claims touting an allergy medication as "smart" or "wise" conferred a clinically meaningful benefit as compared to a competitor's product and should be discontinued, the National Advertising Division recently recommended. Johnson & Johnson, the maker of Zyrtec, challenged claims made by Chattem Inc. for its Xyzal Allergy 24HR medication, including "A Smart Formulation is NOW a Wise OTC Choice for Allergy Sufferers," "Wisely Designed to be Different," "See why a Smart Molecule matters" and "Delivers Potency With a Smart Design."